Participation in the Eastern Cooperative Oncology Group

简介（由申请人提供）：新泽西癌症研究所（CINJ）是NCI指定的综合癌症中心，致力于开展与癌症教育、预防、诊断和治疗相关的实验室、临床和转化研究。自CINJ成立以来，CINJ和我们对ECOG的参与稳步增长，我们在ECOG的累积（3年累积284项和434项随访）、委员会参与（17项委员会参与）、方案领导（7项活跃研究和1项提交研究）和出版物（23项）方面投入了更多的资源。CINJ最近还获得了ECOG预防中心的批准，并成为ECOG症状管理联盟的成员。CINJ的几位研究人员已经获得了nci资助的ECOG相关研究的批准。基于我们患者基数的持续增长（每年4000例新病例），我们附属网络的增长（18家医院，每年14000例新病例），以及我们对多个疾病领域ECOG累积的承诺，我们预计我们的累积，我们的科学和管理角色将继续增长。因此，CINJ被定位为该组织中较大的主要贡献者之一。我们建议将这笔拨款用于：1)继续我们在ECOG疾病导向、行政和模式委员会的代表；2)设计并积极参与新的多模态研究；3)提供同行评审、资助的机构实验室，作为群体科学的潜在资源；4)监测患者入院情况、方案遵守情况和数据质量；5)及时提交完整的数据表格；6)与其他西非经共体成员国合作，继续在CINJ开展试点研究；加强我们的基础科学实验室和集团临床试验项目之间的互动。

DESCRIPTION (provided by applicant): The Cancer Institute of New Jersey (CINJ) is an NCI Designated Comprehensive Cancer Center committed to the conduct of laboratory, clinical, and translational research relevant to cancer education, prevention, diagnosis and treatment. CINJ and our participation in ECOG have grown steadily since CINJ's recent inception, and we are committing even greater resources to ECOG in accrual (3year accrual of 284 and 434 follow-up), committee participation (17 committee participations), protocol leadership (7 active and 1 submitted study), and publications (23). CINJ also recently received approval as an ECOG Prevention Center, and as a member of the ECOG Symptom Management Consortium. Several of the CINJ investigators already received approval for NCI-funded ECOG correlative studies grants. Based on the continued growth of our patient base (>4000 new cases/year), the growth of our Affiliate Network (18 hospitals with >14,000 new cases), and our commitment to ECOG accrual in multiple disease areas, we expect our accrual, our scientific and our administrative roles to continue to grow. CINJ is thus positioned to become one of the larger main member contributors to the group. We propose to use this grant to: 1) continue our representation on ECOG disease oriented, administrative, and modality committees; 2) design and participate actively in new multi-modality studies; 3) offer peer reviewed, funded institutional laboratories as potential resources for group science; 4) monitor patient entry, protocol compliance, and data quality; 5) submit complete data forms in a timely manner, 6) continue development of pilot studies at the CINJ in collaboration with other ECOG members ; and 7) enhance interaction between the our basic science laboratories and the group's clinical trials program.